Kevzara

Brand name: Kevzara
Generic name: sarilumab
FDA approved use: severe active rheumatoid arthritis
Limitations: Not recommended in patients with an absolute neutrophil count less than 2000 per mm^3, platelet count less than 150,000 per mm^3, or patients who have Alt or Ast above 1.5 times the upper limit of normal (ULN).  Not recommended in patients who test positive for latent tuberculosis (treat TB first).  Avoid in patients who are using biologic DMARDs (increase immunosuppressive effect and increase risk for infections).  Finally, avoid in patients with active infections
Dosage forms and strength: Injection: 150 mg/1.14 mL or 200 mg/1.14 mL solution in a single-dose pre-filled syringe 
Recommended Dosage: 200 mg once every 2 weeks.  Reduce dose to 150 mg once every two weeks for management of neutropenia, thrombocytopenia, and elevated liver enzyme.
Adverse Reaction: Serious infections, neutropenia, thrombocytopenia, GI perforation, immunosuppression, hypersensitivity reactions
MOA: Human monoclonal antibody that antagonizes Interleukin-6 

This medication can be used monotherapy or in combination with methotrexate or other conventional DMARDS.  This needs to be injected by healthcare professional.  This injection needs to be at room temperature before injecting it.  

This drug interacts with CYP3A4 pathway.  Take into caution if patient is on other CYP3A4 medications.

Structure

Purple is sarilumab


Sources
official website
Package insert
how to inject/patient information